LONDON, May 19, 2015 /PRNewswire/ -- This BCC Research report explores the present and future strategies within the bioengineered protein drugs market. It analyzes each market and its applications, regulatory environment, technologies involved, market projections and market shares. Revenues are broken down by region. CAGR projections are estimated for the five-year period from 2014 through 2019. The report also covers significant patents and their allotments in each category.
Use this report to:
- Receive information about the current and future global market for bioengineered protein drugs.
- Receive information on diseases for which protein drugs are particularly amenable including hemophilia, diabetes, cancer, cystic fibrosis, hepatitis, psoriasis, and congenital
diseases.
- Analyze the industry structure of bioengineered protein drugs.
- Learn about the significant patents and their allotments in each category.
Highlights
- The global market for bioengineered protein drugs was valued at $151.9 billion in 2013 and will reach about $157.0 billion in 2014. The market is further expected to grow to about $222.7 billion in 2019, a compound annual growth rate (CAGR) of 7.2% from 2014 through 2019.
- The U.S. is the largest regional segment of the market; anticipated to be at $72 billion in 2014 and $111 billion by 2019, increasing at a CAGR of 9.1% from 2014 through 2019.
- The European region should reach $38.8 billion in 2014 and nearly $55.4 billion by 2019 at a 7.4% CAGR for the period 2014-2019.
INTRODUCTION
STUDY OBJECTIVES
Proteins play a crucial role in living organisms. They play an important part in defining both structure as well as function. In recent years, technology advances has led to the
development of advanced techniques for controlled and effective delivery of peptides and proteins in the body. This has led to their efficient use in treating human injury and effective targeted treatments to prevent a number of life-threatening diseases. Furthermore, these drugs are useful as preventive vaccinations, blood-clotting factors,
etc. The objective of this report is to provide an overview of the current and future global market for bioengineered protein drugs. The objective is to present a comprehensive analysis of the future direction of bioengineered protein drugs in terms of an important tool for the use of protein-based drugs.
This report explores the present and future strategies within the bioengineered protein drugs market. Drug categories included in this report are monoclonal antibodies,
cytokines, peptide hormones, therapeutic enzymes, vaccines, blood factors and peptide antibiotics. The inventiveness of the market, the setbacks and the needs of the
market are discussed in this report. Usage of these types of drugs in various disease sectors is also depicted in this report. Diseases for which protein drugs are particularly
responsive are also discussed in this report, and include diabetes, cancer, blood disorders and skin diseases, growth hormone disorder, enzyme disorder and fertility
disorder and others. A detailed analysis industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2014 through 2019. The report also covers significant patents and their allotments in each category.
REASONS FOR DOING THIS STUDY
The bioengineered protein drug market is one of the fastest growing markets in recent years in the overall pharmaceutical/biotechnology markets. These drugs have gained
much attention from pharmaceutical companies due to their bioreactivity, specificity, safety and overall success rate in treating disease. Extensive research in the field of
these protein drugs has revealed their usefulness in being able to provide therapeutic treatments for various diseases. R&D spending, along with increasing competition,
patent expiries and new technologies, are directing these drugs to a new direction. The progress in technology, as well as new product launches, has influenced market growth. Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type of bioengineered proteins in light of the new technologies, growing competition and changing customer needs.
INTENDED AUDIENCE
This study covers the areas of market growth in bioengineered protein drugs manufacturers and users. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.
SCOPE OF THE STUDY
The scope of this study involves the bioengineered protein therapeutics used in the pharmaceutical and the biopharmaceutical markets. BCC Research analyzes each
market and its applications, regulatory environment, technologies involved, market projections and market shares. The technological issues include all the latest trends,
pipeline products and developments. The emerging markets cover countries such as India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc. The bioengineered protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, enzymes, peptide hormones and blood factors. These products are bioengineered and are produced by recombinant DNA technology. The only blood products considered in this report are recombinant blood products which are derived through the recombinant DNA technology process.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical
newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of bioengineered protein drug experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
Download the full report: https://www.reportbuyer.com/product/2354690/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article